You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Sun Pharma to launch Merck's Covid pill under brand name 'Molxvir' in India

Sun Pharmaceutical Industries said it is gearing up to introduce Merck Sharp Dohme and Ridgeback's molnupiravir under the brand name Molxvir in India

Topics
Coronavirus | Sun Pharma

Press Trust of India  |  New Delhi 

Sun Pharma

Sun Pharmaceutical Industries on Thursday said it is gearing up to introduce Merck Sharp Dohme (MSD) and Ridgeback's molnupiravir under the brand name Molxvir in India.

The Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COVID-19 in adults in India.

Earlier this year, had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir in India and to over 100 low- and middle-income countries.

Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 in adults.

It is under review by the US Food and Drug Administration for the emergency use authorisation.

"The recent authorisation of molnupiravir, licensed from MSD and Ridgeback, by the UK regulator is a positive step.

"In line with our consistent efforts to accelerate access to new drugs for COVID-19 treatment, we are gearing up to make Molxvir available to patients and healthcare providers across India at an economical price post approval by DCGI," India Business CEO Kirti Ganorkar said in a statement.

Molxvir will be manufactured at one of the company's plants in India and it has enough capacity to meet the demand, he added.

In the Phase-III trial by Merck, Molnupiravir significantly reduced the risk of hospitalisation or death by around 50 per cent in a planned interim analysis of the MOVe-OUT trial in at risk, non-hospitalised adult patients with mild-to-moderate COVID-19.

Additionally, based on the participants with available viral sequencing data (around 40 per cent of participants), molnupiravir demonstrated consistent efficacy across viral variants like Gamma, Delta and Mu.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 11 2021. 19:29 IST
RECOMMENDED FOR YOU